CN Patent

CN116019921A — 用于治疗癌症的组合疗法

Assigned to Epizyme Inc · Expires 2023-04-28 · 3y expired

What this patent protects

本发明涉及包含人类组蛋白甲基转移酶EZH2的抑制剂和一种或多种其它治疗药剂、尤其是抗癌药剂例如强的松的组合物，并且涉及用于向对其有需要的受试者进行给药以治疗癌症的组合疗法方法。

USPTO Abstract

本发明涉及包含人类组蛋白甲基转移酶EZH2的抑制剂和一种或多种其它治疗药剂、尤其是抗癌药剂例如强的松的组合物，并且涉及用于向对其有需要的受试者进行给药以治疗癌症的组合疗法方法。

Drugs covered by this patent

tazemetostat-hydrobromide (TAZEMETOSTAT HYDROBROMIDE)

Patent Metadata

Patent number: CN116019921A
Jurisdiction: CN
Classification: —
Expires: 2023-04-28
Drug substance claim: No
Drug product claim: No
Assignee: Epizyme Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.